Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarpogrelate/Aspirin vs Aspirin on Blood Viscosity in PAD and CAD
NCT05730621Phase 4Completed
- Sponsor
- Yuhan
- Start
- Jan 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sarpogrelate in Peripheral Arterial Disease (PAD) and coronary artery disease (CAD) (2 arms), sponsored by Yuhan. Primary endpoint: Change from baseline in Blood Viscosity at 12 weeks. Started Jan 2023; status: completed.
02
Drugs
sarpogrelate
03
Conditions
Peripheral Arterial Disease (PAD)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05730621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05730621.